Tarsus Pharmaceuticals (TARS) Expected to Announce Quarterly Earnings on Tuesday

Tarsus Pharmaceuticals (NASDAQ:TARS) is expected to be issuing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $114.2180 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. The company had revenue of $102.66 million for the quarter, compared to analyst estimates of $95.81 million. On average, analysts expect Tarsus Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tarsus Pharmaceuticals Trading Down 0.2%

Shares of Tarsus Pharmaceuticals stock opened at $68.81 on Friday. The company has a current ratio of 5.26, a quick ratio of 5.21 and a debt-to-equity ratio of 0.22. Tarsus Pharmaceuticals has a 12-month low of $38.51 and a 12-month high of $76.81. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -29.53 and a beta of 0.81. The firm’s 50 day simple moving average is $61.65 and its two-hundred day simple moving average is $50.54.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright upped their price objective on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a report on Monday, October 20th. Finally, Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $69.33.

Insiders Place Their Bets

In related news, Director William J. Phd Link sold 27,116 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the sale, the director directly owned 143,332 shares of the company’s stock, valued at approximately $8,169,924. This represents a 15.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total transaction of $332,220.00. Following the sale, the chief executive officer directly owned 812,106 shares in the company, valued at $44,966,309.22. This trade represents a 0.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 39,116 shares of company stock worth $2,177,832 over the last three months. 8.97% of the stock is currently owned by insiders.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Federated Hermes Inc. boosted its holdings in Tarsus Pharmaceuticals by 0.6% during the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after buying an additional 339 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Tarsus Pharmaceuticals by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock worth $1,137,000 after buying an additional 1,217 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Tarsus Pharmaceuticals by 2.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock worth $3,659,000 after buying an additional 1,394 shares in the last quarter. Canada Pension Plan Investment Board boosted its holdings in Tarsus Pharmaceuticals by 21.4% during the second quarter. Canada Pension Plan Investment Board now owns 8,500 shares of the company’s stock worth $344,000 after buying an additional 1,500 shares in the last quarter. Finally, Osaic Holdings Inc. raised its position in Tarsus Pharmaceuticals by 779.1% during the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after acquiring an additional 2,462 shares during the period. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.